RBC Capital lowered the firm’s price target on Pharming (PHAR) to EUR 1.60 from EUR 1.65 and keeps an Outperform rating on the shares.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PHAR: